{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:59:06Z","timestamp":1794081546497,"version":"4.8.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Any successful strategy to prevent and control HCV infection requires an understanding of the epidemic behaviour among the different genotypes. Here, we performed the first characterization of the epidemic history and transmission dynamics of HCV subtypes in Portugal. Direct sequencing of NS5B was performed on 230 direct-acting antiviral drugs (DAA)-treatment na\u00efve patients in Lisbon. Phylogenetic analysis was used for subtyping and transmission cluster identification. Bayesian methods were used to reconstruct the epidemic history of HCV subtypes. Sequences were analysed for resistance-associated substitutions (RAS). The majority of strains were HCV-GT1 (62.6%), GT3 (18.3%, all subtype 3a) and GT4 (16.1%). Among GT1, the most frequent were subtypes 1a (75.5%) and 1b (24.5%). Polyphyletic patterns were found in all but 12 lineages suggesting multiple introductions of the different subtypes in this population. Five distinct epidemics were identified. The first significant HCV epidemic in Portugal occurred between 1930s and 1960s, was caused almost exclusively by GT1b and was likely associated with blood transfusions. Rapid expansion of GT3a occurred in the 1960s and GT1a in the 1980s, associated with intravenous drug use. The most recent epidemics were caused by GT4a and GT4d and seem to be associated with the resurgence of opioid use. The C316N substitution was found in 31.4% of GT1b-patients. Close surveillance of patients bearing this mutation and undergoing dasabuvir-based regimens will be important to determine its impact on treatment outcome.<\/jats:p>","DOI":"10.1038\/s41598-018-30528-0","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T11:36:43Z","timestamp":1533901003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Epidemic history of hepatitis C virus genotypes and subtypes in Portugal"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8148-0928","authenticated-orcid":false,"given":"Claudia","family":"Palladino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeanyi Jude","family":"Ezeonwumelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rute","family":"Marcelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Moranguinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Serejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Fernando","family":"Velosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Tato","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Taveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"30528_CR1","unstructured":"World Health Organization. Global hepatitis report, 2017. ISBN 978-92-4-156545-5 (2017)."},{"key":"30528_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith, D. B. et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 59, 318\u2013327 (2014).","journal-title":"Hepatology"},{"key":"30528_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1099\/0022-1317-74-11-2391","volume":"74","author":"P Simmonds","year":"1993","unstructured":"Simmonds, P. et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74, 2391\u20132399 (1993).","journal-title":"J. Gen. Virol."},{"key":"30528_CR4","unstructured":"Smith, D. B. et al. International Committee on Taxonomy of Viruses (ICTV). HCV Classification. A web resource to manage the classification and genotype and subtype assignments of hepatitis C virus. at https:\/\/talk.ictvonline.org\/ictv_wikis\/flaviviridae\/w\/sg_flavi\/56\/hcv-classification (2017)."},{"key":"30528_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2015.10.002","volume":"16","author":"OG Pybus","year":"2016","unstructured":"Pybus, O. G. & Th\u00e9z\u00e9, J. Hepacivirus cross-species transmission and the origins of the hepatitis C virus. Curr. Opin. Virol. 16, 1\u20137 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"30528_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach, S. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161\u2013176 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"30528_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/(SICI)1096-9071(199806)55:2<92::AID-JMV2>3.0.CO;2-I","volume":"55","author":"D Jeannel","year":"1998","unstructured":"Jeannel, D. et al. Evidence for High Genetic Diversity and Long-Term Endemicity of Hepatitis C Virus Genotypes 1 and 2 in West Africa. J. Med. Virol. 55, 92\u201397 (1998).","journal-title":"J. Med. Virol."},{"key":"30528_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1099\/vir.0.011569-0","volume":"90","author":"PV Markov","year":"2009","unstructured":"Markov, P. V. et al. Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J. Gen. Virol. 90, 2086\u20132096 (2009).","journal-title":"J. Gen. Virol."},{"key":"30528_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962\u2013973 (2005).","journal-title":"Hepatology"},{"key":"30528_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.meegid.2014.08.005","volume":"27","author":"I Ur Rehman","year":"2014","unstructured":"Ur Rehman, I. et al. Genetic history of hepatitis C virus in Pakistan. Infect. Genet. Evol. 27, 318\u2013324 (2014).","journal-title":"Infect. Genet. Evol."},{"key":"30528_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.virol.2014.07.006","volume":"464\u2013465","author":"JC Iles","year":"2014","unstructured":"Iles, J. C. et al. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. Virology 464\u2013465, 233\u2013243 (2014).","journal-title":"Virology"},{"key":"30528_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1128\/JVI.01501-08","volume":"83","author":"OG Pybus","year":"2009","unstructured":"Pybus, O. G. et al. Genetic History of Hepatitis C Virus in East Asia. J. Virol. 83, 1071\u20131082 (2009).","journal-title":"J. Virol."},{"key":"30528_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1128\/JCM.02831-14","volume":"53","author":"DG Murphy","year":"2015","unstructured":"Murphy, D. G. et al. Hepatitis C virus genotype 7, a new genotype originating from Central Africa. J. Clin. Microbiol. 53, 967\u2013972 (2015).","journal-title":"J. Clin. Microbiol."},{"key":"30528_CR14","doi-asserted-by":"publisher","first-page":"11223","DOI":"10.1128\/JVI.02106-15","volume":"89","author":"AL McNaughton","year":"2015","unstructured":"McNaughton, A. L. et al. Spatiotemporal Reconstruction of the Introduction of Hepatitis C Virus into Scotland and Its Subsequent Regional Transmission. J. Virol. 89, 11223\u201311232 (2015).","journal-title":"J. Virol."},{"key":"30528_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.meegid.2004.08.001","volume":"5","author":"OG Pybus","year":"2005","unstructured":"Pybus, O. G., Cochrane, A., Holmes, E. C. & Simmonds, P. The hepatitis C virus epidemic among injecting drug users. Infect. Genet. Evol. 5, 131\u2013139 (2005).","journal-title":"Infect. Genet. Evol."},{"key":"30528_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","volume":"48","author":"JI Esteban","year":"2008","unstructured":"Esteban, J. I., Sauleda, S. & Quer, J. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol. 48, 148\u2013162 (2008).","journal-title":"J. Hepatol."},{"key":"30528_CR17","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","volume":"13","author":"MJ Alter","year":"2007","unstructured":"Alter, M. J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13, 2436\u20132441 (2007).","journal-title":"World J. Gastroenterol."},{"key":"30528_CR18","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.3748\/wjg.v13.i36.4808","volume":"13","author":"J Timm","year":"2007","unstructured":"Timm, J. & Roggendorf, M. Sequence diversity of hepatitis C virus: Implications for immune control and therapy. World J. Gastroenterol. 13, 4808\u20134817 (2007).","journal-title":"World J. Gastroenterol."},{"key":"30528_CR19","doi-asserted-by":"crossref","unstructured":"Prentoe, J., Vel\u00e1zquez-Moctezuma, R., Foung, S. K. H., Law, M. & Bukh, J. Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. 64, 1881\u20131892 (2016).","DOI":"10.1002\/hep.28705"},{"key":"30528_CR20","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/hep.26524","volume":"58","author":"J Pedersen","year":"2013","unstructured":"Pedersen, J. et al. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology 58, 1587\u20131597 (2013).","journal-title":"Hepatology"},{"key":"30528_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"M Fried","year":"2002","unstructured":"Fried, M., Shiffman, M. L. & Reddy, K. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"S Hadziyannis","year":"2004","unstructured":"Hadziyannis, S. et al. Peginterferon-\u03b12a and ribavirin combination therapy in chronic hepatitis c: A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346\u2013355 (2004).","journal-title":"Ann. Intern. Med."},{"key":"30528_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns, M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958\u2013965 (2001).","journal-title":"Lancet"},{"key":"30528_CR24","first-page":"124","volume":"357","author":"A Mangia","year":"2005","unstructured":"Mangia, A. et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357, 124\u2013134 (2005).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/gut.2004.057182","volume":"54","author":"SM Kamal","year":"2005","unstructured":"Kamal, S. M. et al. Peginterferon \u03b1\u22122b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 54, 858\u2013866 (2005).","journal-title":"Gut"},{"key":"30528_CR26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","volume":"146","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky, J. M. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 146, 1176\u20131192 (2014).","journal-title":"Gastroenterology"},{"key":"30528_CR27","unstructured":"Food and Drug Administration (FDA). Hepatitis B and C Treatments. A complete list of currently approved FDA therapies to treat Hepatitis B and C. at http:\/\/www.fda.gov\/ForPatients\/Illness\/HepatitisBC\/ucm408658.htm (2017)."},{"key":"30528_CR28","unstructured":"European Medicines Agency (EMA). European public assessment reports. at http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&startLetter=View all&searchTab=&keyword=Enter keywords&searchType=name&alreadyLoaded=true&status=Authorised&jsenabled=false&searchGenericType=generi (2017)."},{"key":"30528_CR29","first-page":"338","volume":"13","author":"M G\u00f6tte","year":"2016","unstructured":"G\u00f6tte, M. & Feld, J. J. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat. Publ. Gr. 13, 338\u2013351 (2016).","journal-title":"Nat. Publ. Gr."},{"key":"30528_CR30","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368, 1878\u20131887 (2013).","journal-title":"N Engl J Med"},{"key":"30528_CR31","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"I Jacobson","year":"2013","unstructured":"Jacobson, I. et al. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. N Engl J Med 368, 1867\u20131877 (2013).","journal-title":"N Engl J Med"},{"key":"30528_CR32","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem, S. et al. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N. Engl. J. Med. 370, 1993\u20132001 (2014).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski, M. S. et al. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. JAMA 312, 353\u201361 (2014).","journal-title":"JAMA"},{"key":"30528_CR34","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2017","unstructured":"Lawitz, E. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384, 1756\u20131765 (2017).","journal-title":"Lancet"},{"key":"30528_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/hep.28467","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo, P. et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64, 370\u2013380 (2016).","journal-title":"Hepatology"},{"key":"30528_CR36","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N. Engl. J. Med. 370, 1889\u20131898 (2014).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR37","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483\u201393 (2014).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR38","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley, K. V. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879\u201388 (2014).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourli\u00e8re","year":"2015","unstructured":"Bourli\u00e8re, M. et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect. Dis. 15, 397\u2013404 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"30528_CR40","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld, J. J. et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N. Engl. J. Med. 373, 2599\u20132607 (2015).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR41","unstructured":"Gilead Sciences, I. Highlights of Prescribing Information: Harvoni (ledipasvir and sofosbuvir). Foster City, CA. 1\u201341 at http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf. (2016)."},{"key":"30528_CR42","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster, G. R. et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N. Engl. J. Med. 373, 2599\u20132607 (2015).","journal-title":"N. Engl. J. Med."},{"key":"30528_CR43","doi-asserted-by":"publisher","unstructured":"Curry, M. P. et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N. Engl. J. Med. 151116123036000, https:\/\/doi.org\/10.1056\/NEJMoa1512614 (2015).","DOI":"10.1056\/NEJMoa1512614"},{"key":"30528_CR44","doi-asserted-by":"crossref","unstructured":"Highlights of Prescribing Information for VIEKIRA PAK. 1\u201351 (2016).","DOI":"10.1155\/2016\/8627139"},{"key":"30528_CR45","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1128\/AAC.02386-13","volume":"58","author":"VC Di Maio","year":"2014","unstructured":"Di Maio, V. C. et al. Hepatitis c virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors. Antimicrob. Agents Chemother. 58, 2781\u20132797 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30528_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12985-015-0414-1","volume":"12","author":"A Costantino","year":"2015","unstructured":"Costantino, A. et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-na\u00efve patients with chronic hepatitis C. Virol. J. 12, 186 (2015).","journal-title":"Virol. J."},{"key":"30528_CR47","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/S0168-8278(17)31427-7","volume":"66","author":"J Chhatwal","year":"2017","unstructured":"Chhatwal, J. et al. Projection of patients who fail treatment in the era of direct-acting antivirals. J. Hepatol. 66, S512\u2013S513 (2017).","journal-title":"J. Hepatol."},{"key":"30528_CR48","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1097\/QAD.0b013e32836381cc","volume":"27","author":"TCS Martin","year":"2013","unstructured":"Martin, T. C. S. et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids 27, 2551\u20132557 (2013).","journal-title":"Aids"},{"key":"30528_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","volume":"66","author":"P Ingiliz","year":"2017","unstructured":"Ingiliz, P. et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J. Hepatol. 66, 282\u2013287 (2017).","journal-title":"J. Hepatol."},{"key":"30528_CR50","unstructured":"Ingiliz, P. et al. High Incidence of HCV Reinfection in HIV-positive MSM in the DAA Era. in 16th European AIDS Conference; 2017 Oct 25-27; Milan, Italy at http:\/\/mediatheque.cyim.com\/mediatheque\/media.aspx?mediaId=34876&channel=28172 (2017)."},{"key":"30528_CR51","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Statistical Bulletin 2017. at http:\/\/www.emcdda.europa.eu\/data\/stats2017 (2017)."},{"key":"30528_CR52","unstructured":"Funda\u00e7\u00e3o Francisco Manuel dos Santos. PORDATA, Base de Dados de Portugal Contempor\u00e2neo. at http:\/\/www.pordata.pt\/Portugal (2017)."},{"key":"30528_CR53","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/MEG.0000000000000608","volume":"28","author":"SC Carvalhana","year":"2016","unstructured":"Carvalhana, S. C., Leit\u00e3o, J., Alves, A. C., Bourbon, M. & Cortez-Pinto, H. Hepatitis B and C prevalence in Portugal. Eur. J. Gastroenterol. Hepatol. 28, 640\u2013644 (2016).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"30528_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpg.2014.03.001","volume":"21","author":"J Anjo","year":"2014","unstructured":"Anjo, J. et al. O impacto da hepatite C em Portugal. GE J. Port. Gastrenterologia 21, 44\u201354 (2014).","journal-title":"GE J. Port. Gastrenterologia"},{"key":"30528_CR55","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1046\/j.1440-1746.2001.2574a.x","volume":"16","author":"RT Marinho","year":"2001","unstructured":"Marinho, R. T., Moura, M. C., Giria, J. A. & Ferrinho, P. Epidemiological aspects of hepatitis C in Portugal. J. Gastroenterol. Hepatol. 16, 1076\u20131079 (2001).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"30528_CR56","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Glob. Hepat. Program. Dep. HIV\/AIDS 56, WHO\/HIV\/2016.06 (2016)."},{"key":"30528_CR57","unstructured":"Minist\u00e9rio da Sa\u00fade. Dire\u00e7\u00e3o-Geral da Sa\u00fade. Programa nacional para as hepatites virais 2017. at https:\/\/www.dgs.pt\/documentos-e-publicacoes\/relatorio-do-programa-nacional-para-as-hepatites-virais-2017.aspx (2017)."},{"issue":"1","key":"30528_CR58","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1111\/j.1432-2277.1998.tb01093.x","volume":"11","author":"A Rodrigues","year":"1998","unstructured":"Rodrigues, A. et al. Hepatitis C virus genotypes and the influence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients. Transpl. Int. 11(1), S115\u20138 (1998).","journal-title":"Transpl. Int."},{"key":"30528_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jinf.2006.11.010","volume":"54","author":"R Sarmento-Castro","year":"2007","unstructured":"Sarmento-Castro, R. et al. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection. J. Infect. 54, 609\u2013616 (2007).","journal-title":"J. Infect."},{"key":"30528_CR60","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1023\/A:1005442317680","volume":"45","author":"F Ramalho","year":"2000","unstructured":"Ramalho, F. et al. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig. Dis. Sci. 45, 182\u2013187 (2000).","journal-title":"Dig. Dis. Sci."},{"key":"30528_CR61","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/jmv.21955","volume":"83","author":"RA Calado","year":"2011","unstructured":"Calado, R. A. et al. Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J. Med. Virol. 83, 608\u2013615 (2011).","journal-title":"J. Med. Virol."},{"key":"30528_CR62","doi-asserted-by":"publisher","first-page":"695","DOI":"10.20344\/amp.6257","volume":"28","author":"E Padua","year":"2015","unstructured":"Padua, E., Avo, A. P., Almeida, C., Agua Doce, I. & Cortes Martins, H. Assessment of Hepatitis C Virus Diversity in Addition to the Frequency of Genotypes in Samples Analyzed Between 2009 and 2014 at the Reference Laboratory of National Health Institute Dr. Ricardo Jorge. Acta Med. Port. 28, 695\u2013701 (2015).","journal-title":"Acta Med. Port."},{"key":"30528_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77\u201387 (2015).","journal-title":"Hepatology"},{"key":"30528_CR64","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2015","unstructured":"Kati, W. et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis c virus polymerase inhibitor. Antimicrob. Agents Chemother. 59, 1505\u20131511 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30528_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcv.2016.05.010","volume":"81","author":"V Kartashev","year":"2016","unstructured":"Kartashev, V. et al. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J. Clin. Virol. 81, 82\u201389 (2016).","journal-title":"J. Clin. Virol."},{"key":"30528_CR66","doi-asserted-by":"publisher","unstructured":"Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A. & Cacciapuoti, C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World Journal of Gastroenterology, https:\/\/doi.org\/10.3748\/wjg.v22.i34.7824 (2016).","DOI":"10.3748\/wjg.v22.i34.7824"},{"key":"30528_CR67","doi-asserted-by":"publisher","first-page":"359 LP","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (80-.). 244, 359 LP\u2013362 (1989).","journal-title":"Science (80-.)."},{"key":"30528_CR68","doi-asserted-by":"publisher","first-page":"362 LP","DOI":"10.1126\/science.2496467","volume":"244","author":"G Kuo","year":"1989","unstructured":"Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (80-.). 244, 362 LP\u2013364 (1989).","journal-title":"Science (80-.)."},{"key":"30528_CR69","doi-asserted-by":"publisher","unstructured":"Moreira, M., Hughes, B., Costa Storti, C. & Zobel, F. EMCDDA. Drug Policy Profile: Portugal. Drug Policy Profile 26 pp., https:\/\/doi.org\/10.2810\/41390 (2011).","DOI":"10.2810\/41390"},{"key":"30528_CR70","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Trends in injecting drug use in Europe. Selected Issue 34, (2010)."},{"key":"30528_CR71","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(16)00619-X","volume":"387","author":"J Csete","year":"2016","unstructured":"Csete, J. et al. Public health and internacional drug policy. Lancet 387, 1427\u20131480 (2016).","journal-title":"Lancet"},{"key":"30528_CR72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00705-008-0270-z","volume":"154","author":"D Koletzki","year":"2009","unstructured":"Koletzki, D. et al. Full genome sequence of three isolates of hepatitis C virus subtype 4b from Portugal. Arch. Virol. 154, 127\u2013132 (2009).","journal-title":"Arch. Virol."},{"key":"30528_CR73","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1128\/JCM.01146-09","volume":"47","author":"J De Bruijne","year":"2009","unstructured":"De Bruijne, J. et al. Emergence of hepatitis C virus genotype 4: Phylogenetic analysis reveals three distinct epidemiological profiles. J. Clin. Microbiol. 47, 3832\u20133838 (2009).","journal-title":"J. Clin. Microbiol."},{"key":"30528_CR74","doi-asserted-by":"crossref","unstructured":"Wiessing, L. et al. Hepatitis C virus infection epidemiology among people who inject drugs in europe: A systematic review of data for scaling up treatment and prevention. PLoS One 9 (2014).","DOI":"10.1371\/journal.pone.0103345"},{"key":"30528_CR75","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/molbev\/msg043","volume":"20","author":"OG Pybus","year":"2003","unstructured":"Pybus, O. G., Drummond, A. J., Nakano, T., Robertson, B. H. & Rambaut, A. The epidemiology and iatrogenic transmission of hepatitis C virus in egypt: A Bayesian coalescent approach. Mol. Biol. Evol. 20, 381\u2013387 (2003).","journal-title":"Mol. Biol. Evol."},{"key":"30528_CR76","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/infdis\/175.3.685","volume":"175","author":"HH Feucht","year":"1997","unstructured":"Feucht, H. H. et al. The influence of age on the prevalence of hepatitis C virus subtypes 1a and 1b. J Infect Dis 175, 685\u2013688 (1997).","journal-title":"J Infect Dis"},{"key":"30528_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1743-422X-5-72","volume":"5","author":"Ma Bracho","year":"2008","unstructured":"Bracho, Ma et al. Complete genome of a European hepatitis C virus subtype 1g isolate: phylogenetic and genetic analyses. Virol. J. 5, 72 (2008).","journal-title":"Virol. J."},{"key":"30528_CR78","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","volume":"18","author":"BE Pickett","year":"2011","unstructured":"Pickett, B. E., Striker, R. & Lefkowitz, E. J. Evidence for separation of HCV subtype 1a into two distinct clades. J. Viral Hepat. 18, 608\u2013618 (2011).","journal-title":"J. Viral Hepat."},{"key":"30528_CR79","doi-asserted-by":"publisher","first-page":"ofv043","DOI":"10.1093\/ofid\/ofv043","volume":"2","author":"A De Luca","year":"2015","unstructured":"De Luca, A. et al. Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors. Open Forum Infect. Dis. 2, ofv043 (2015).","journal-title":"Open Forum Infect. Dis."},{"key":"30528_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"AF Santos","year":"2016","unstructured":"Santos, A. F. et al. In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease. Sci. Rep. 6, 1\u20136 (2016).","journal-title":"Sci. Rep."},{"key":"30528_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41598-017-00038-6","volume":"7","author":"C Palladino","year":"2017","unstructured":"Palladino, C. et al. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: A cross-sectional study. Sci. Rep. 7, 3\u20138 (2017).","journal-title":"Sci. Rep."},{"key":"30528_CR82","doi-asserted-by":"crossref","unstructured":"Svarovskaia, E. S. et al. Infrequent development of resistance in genotype 1-6 hepatitis c virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin. Infect. Dis. 59 (2014).","DOI":"10.1093\/cid\/ciu697"},{"key":"30528_CR83","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","volume":"213","author":"ES Svarovskaia","year":"2016","unstructured":"Svarovskaia, E. S. et al. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. J. Infect. Dis. 213, 1240\u20131247 (2016).","journal-title":"J. Infect. Dis."},{"key":"30528_CR84","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-016-0011-6","volume":"6","author":"ZW Chen","year":"2016","unstructured":"Chen, Z. W., Li, H., Ren, H. & Hu, P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data. Sci. Rep. 6, 4\u201312 (2016).","journal-title":"Sci. Rep."},{"key":"30528_CR85","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/liv.13327","volume":"37","author":"VC Di Maio","year":"2017","unstructured":"Di Maio, V. C. et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 37, 514\u2013528 (2017).","journal-title":"Liver Int."},{"key":"30528_CR86","first-page":"S139","volume":"64","author":"S Susser","year":"2016","unstructured":"Susser, S. et al. European RAVs database: Frequency and characteristics of RAVs in treatment-naive and DAA-experienced patients [Abstract PS007]. The International Liver CongressTMEASL - European Association for the Study of the Liver 64, S139 (2016).","journal-title":"The International Liver CongressTMEASL - European Association for the Study of the Liver"},{"key":"30528_CR87","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1128\/AAC.00998-15","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan, P. et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob. Agents Chemother. 59, 5445\u20135454 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30528_CR88","first-page":"223","volume":"10","author":"R Brand\u00e3o","year":"2018","unstructured":"Brand\u00e3o, R. et al. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018 10, 223 (2018).","journal-title":"Viruses 2018"},{"key":"30528_CR89","doi-asserted-by":"crossref","unstructured":"Bartolini, B. et al. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN\/RBV+ daclatasvir: A case study using ultra deep pyrosequencing. J. Clin. Virol. 66 (2015).","DOI":"10.1016\/j.jcv.2015.02.001"},{"key":"30528_CR90","first-page":"344","volume":"61","author":"E von Elm","year":"2014","unstructured":"von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int. J. Surg. 61, 344\u2013349 (2014).","journal-title":"Int. J. Surg."},{"key":"30528_CR91","first-page":"120","volume":"15","author":"T Leitner","year":"1993","unstructured":"Leitner, T. et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 15, 120\u2013127 (1993).","journal-title":"Biotechniques"},{"key":"30528_CR92","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/hep.21377","volume":"44","author":"C Kuiken","year":"2006","unstructured":"Kuiken, C. et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44, 1355\u20131361 (2006).","journal-title":"Hepatology"},{"key":"30528_CR93","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"30528_CR94","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/molbev\/msp259","volume":"27","author":"M Gouy","year":"2010","unstructured":"Gouy, M., Guindon, S. & Gascuel, O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 27, 221\u2013224 (2010).","journal-title":"Mol. Biol. Evol."},{"key":"30528_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gku739","volume":"42","author":"D Struck","year":"2014","unstructured":"Struck, D., Lawyer, G., Ternes, A. M., Schmit, J. C. & Bercoff, D. P. COMET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 42, 1\u201311 (2014).","journal-title":"Nucleic Acids Res."},{"key":"30528_CR96","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1093\/bioinformatics\/bti607","volume":"21","author":"T de Oliveira","year":"2005","unstructured":"de Oliveira, T. et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21, 3797\u20133800 (2005).","journal-title":"Bioinformatics"},{"key":"30528_CR97","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/nar\/gkp455","volume":"37","author":"LCJ Alcantara","year":"2009","unstructured":"Alcantara, L. C. J. et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res. 37, 634\u2013642 (2009).","journal-title":"Nucleic Acids Res."},{"key":"30528_CR98","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13127-011-0056-0","volume":"12","author":"D Silvestro","year":"2012","unstructured":"Silvestro, D. & Michalak, I. RaxmlGUI: A graphical front-end for RAxML. Org. Divers. Evol. 12, 335\u2013337 (2012).","journal-title":"Org. Divers. Evol."},{"key":"30528_CR99","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gkw290","volume":"44","author":"I Letunic","year":"2016","unstructured":"Letunic, I. & Bork, P. Interactive tree of life (iTOL)v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 44, W242\u2013W245 (2016).","journal-title":"Nucleic Acids Res."},{"key":"30528_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-317","volume":"14","author":"M Ragonnet-Cronin","year":"2013","unstructured":"Ragonnet-Cronin, M. et al. Automated analysis of phylogenetic clusters. BMC Bioinformatics 14, 317 (2013).","journal-title":"BMC Bioinformatics"},{"key":"30528_CR101","doi-asserted-by":"publisher","first-page":"e101738","DOI":"10.1371\/journal.pone.0101738","volume":"9","author":"AC Pineda-Pe\u00f1a","year":"2014","unstructured":"Pineda-Pe\u00f1a, A. C. et al. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic. PLoS One 9, e101738 (2014).","journal-title":"PLoS One"},{"key":"30528_CR102","doi-asserted-by":"crossref","unstructured":"Rose, R. et al. Identifying Transmission Clusters with Cluster Picker and HIV-TRACE. AIDS Research and Human Retroviruses 33 (2017).","DOI":"10.1089\/aid.2016.0205"},{"key":"30528_CR103","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/molbev\/mss075","volume":"29","author":"AJ Drummond","year":"2012","unstructured":"Drummond, A. J., Suchard, M. A., Xie, D. & Rambaut, A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 29, 1969\u20131973 (2012).","journal-title":"Mol. Biol. Evol."},{"key":"30528_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/molbev\/msj021","volume":"23","author":"B Shapiro","year":"2006","unstructured":"Shapiro, B., Rambaut, A. & Drummond, A. J. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol. Biol. Evol. 23, 7\u20139 (2006).","journal-title":"Mol. Biol. Evol."},{"key":"30528_CR105","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2148-11-131","volume":"11","author":"RR Gray","year":"2011","unstructured":"Gray, R. R. et al. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol. Biol. 11, 131 (2011).","journal-title":"BMC Evol. Biol."},{"key":"30528_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/srep44947","volume":"7","author":"AA Al-Qahtani","year":"2017","unstructured":"Al-Qahtani, A. A. et al. The epidemic dynamics of hepatitis C virus subtypes 4a and 4d in Saudi Arabia. Sci. Rep. 7, 44947 (2017).","journal-title":"Sci. Rep."},{"key":"30528_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky, J. M. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 151, 70\u201386 (2016).","journal-title":"Gastroenterology"},{"key":"30528_CR108","first-page":"1","volume":"66","author":"EASL","year":"2016","unstructured":"EASL. EASL Recommendations on Treatment of Hepatitis C European Association for the Study of the Liver. J Hepatol. 66, 1\u201323 (2016).","journal-title":"J Hepatol."},{"key":"30528_CR109","unstructured":"The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. at www.hcvguidelines.org (2017)."},{"key":"30528_CR110","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","volume":"37","author":"MC Sorbo","year":"2018","unstructured":"Sorbo, M. C. et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist. Updat. 37, 17\u201339 (2018).","journal-title":"Drug Resist. Updat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30528-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30528-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30528-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T08:41:50Z","timestamp":1671612110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-30528-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["30528"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-30528-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"16 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12266"}}